Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center

Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center

Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy's drug and poison information center (DPIC). Methods: In this study, data of patients receiving...

Full description

Bibliographic Details
Main Authors: Amirhosein Ghahremanian, Hasti Photography, Sona Ghasemi, Mohammadreza Heidari, Elliyeh ghadrdan
Format: Article
Language:English
Published: Research Center for Rational Use of Drugs (RCRUD) 2023-09-01
Series:Journal of Pharmaceutical Care
Subjects:
Remdesivir, COVID-19, DPIC, Adverse drug events
Online Access:https://jpc.tums.ac.ir/index.php/jpc/article/view/590

Similar Items

Similar Items